Taking Control of Castleman Disease: Leveraging Precision Medicine Technologies to Accelerate Rare Disease Research by Newman, Samantha Kass et al.
Taking Control of Castleman
Disease: Leveraging Precision
Medicine Technologies to
Accelerate Rare Disease Research
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Newman, S. K., R. K. Jayanthan, G. W. Mitchell, J. A. Carreras
Tartak, M. P. Croglio, A. Suarez, A. Y. Liu, et al. 2015. “Taking Control
of Castleman Disease: Leveraging Precision Medicine Technologies
to Accelerate Rare Disease Research.” The Yale Journal of Biology
and Medicine 88 (4): 383-388.
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:23845266
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
383Copyright © 2015
Taking Control of Castleman Disease: 
Leveraging Precision Medicine Technologies
to Accelerate Rare Disease Research
Samantha Kass Newmana,b, Raj K. Jayanthanb,c, Grant W. Mitchellb, Jossie A. Carreras Tartakb,d,
Michael P. Crogliob,e, Alexander Suarezb,d, Amy Y. Liub, Beatrice M. Razzob,d, Enny Oyeniranb,d,
Jason R. Ruthb,f, and David C. Fajgenbaumb,g*
aDepartment of Medicine, NYU Langone Medical Center, New York, New York; bCastleman Disease Collaborative Network,
Philadelphia, Pennsylvania; cSchool of Medicine, Meharry Medical College, Nashville, Tennessee; dPerelman School of 
Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; eSchool of Medicine, Stony Brook University, Stony Brook,
New York; fDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts;
gDivision of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Philadelphia, Pennsylvania
INTRODUCTION
Precision medicine describes the use of an individ-
ual’s “omics” data (genomics, transcriptomics, pro-
teomics, and metabolomics) to guide decisions in clinical
practice. In this approach, the diagnosis, management, and
prevention of disease are tailored or “personalized” to a
specific patient’s profile [1]. This approach is particularly
important for rare diseases, which affect 8 to 10 percent of
the U.S. population [2]. It is estimated that approximately
80 percent of rare diseases have a genetic origin [3], and
the rest of rare diseases are in a position to benefit from
transcriptomics and proteomics technologies that have
been enabled by the “omics” revolution.
“Omics” data can be used to elucidate the etiology of
a rare disease as well as to personalize management for a
particular rare disease patient based on that individual’s
features. An excellent example of a rare disease in which
the precision medicine approach has already enabled
breakthroughs for the etiology of the disease and for per-
sonalizing individual therapies is cystic fibrosis (CF). Se-
quencing was used to identify the causative CFTR
mutation in 1989 and thereafter to develop therapies tar-
geted at the mutation [4]. More recently, there have been
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REVIEW
Castleman disease (CD†) is a rare and heterogeneous disorder characterized by lymphadenopathy that may
occur in a single lymph node (unicentric) or multiple lymph nodes (multicentric), the latter typically occur-
ring secondary to excessive proinflammatory hypercytokinemia. While a cohort of multicentric Castleman
disease (MCD) cases are caused by Human Herpes Virus-8 (HHV-8), the etiology of HHV-8 negative, idio-
pathic MCD (iMCD), remains unknown. Breakthroughs in “omics” technologies that have facilitated the
development of precision medicine hold promise for elucidating disease pathogenesis and identifying novel
therapies for iMCD. However, in order to leverage precision medicine approaches in rare diseases like CD,
stakeholders need to overcome several challenges. To address these challenges, the Castleman Disease Col-
laborative Network (CDCN) was founded in 2012. In the past 3 years, the CDCN has worked to transform
the understanding of the pathogenesis of CD, funded and initiated genomics and proteomics research, and
united international experts in a collaborative effort to accelerate progress for CD patients. The CDCN’s
collaborative structure leverages the tools of precision medicine and serves as a model for both scientific
discovery and advancing patient care.
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two approved drugs that are given to patients based on their
specific defect with the CFTR protein [5]. The field of on-
cology has also benefited, where current drug development
is focused almost entirely on targeted therapy and im-
munologic approaches based on the influence of specific
molecular drivers [6]. For example, the discovery of a chro-
mosomal rearrangement between EML4 and ALK that re-
sults in a fusion protein with kinase activity and is present
in approximately 4 percent of non-small cell lung cancers
led to the development of crizotinib, a protein kinase in-
hibitor targeting ALK [7]. There are also examples of rare
diseases that are highly heterogeneous, which may have less
penetrant genes, such as Amyotrophic Lateral Sclerosis
(ALS). Though multiple SNPs have been associated with
ALS, a single gene has not been identified — yet [8].
The precision medicine approach may allow for im-
proved clinical decision-making and facilitate the delivery
of customized therapies that may be more effective than
standard treatments. The benefits of precision medicine ex-
tend broadly from identifying high-risk individuals to en-
hancing prevention strategies and minimizing exposure to
ineffective or toxic therapies. These effects all serve to re-
duce health care costs, optimize patient care, and improve
patient quality of life [9]. Furthermore, research suggests
that an understanding of personal genetic information in-
creases patient compliance and participation in care [10,11]. 
Recognizing the value of the precision medicine ap-
proach, the U.S. government proposed the Precision Medi-
cine Initiative in February 2015, promoting the use of
genetic databases and advances in molecular biology, ge-
nomics, and bioinformatics in order to personalize health
care [6]. The ability to practice precision medicine is largely
due to the completion of the Human Genome Project (HGP),
and the development of proteomics, metabolomics, ge-
nomics, and transcriptomics approaches to study biology and
disease [1,6]. While genetic research was responsible for
major breakthroughs in medicine prior to the completion of
the HGP, the sequencing of the complete human genome has
facilitated genetic research on a massive scale, fundamen-
tally changing our understanding of all diseases, including
those that did not have a strong heritable phenotype. Pro-
teomics describes the analysis of proteins in a biological
sample and is performed through a variety of methods. RNA
sequencing is also available, thanks to the field of transcrip-
tomics, which uses microarray analysis to assess cellular,
genetic, and environmental effects on gene expression [1].
Metabolomics characterizes metabolic profiles by using
mass spectrometry or magnetic resonance spectroscopy to
assess how specific metabolites relate to different pathways
[12]. In addition to whole genome sequencing, single-gene
tests may be performed to evaluate risk for inherited dis-
eases, the most notable example being BRCA testing for
breast cancer. Disorders thought to have multi-factorial ori-
gins can be risk stratified using genetic panels, which se-
quence for mutations within different genes associated with
a common phenotype [1]. It is further possible to predict a
patient’s response to therapy, thanks to pharmacogenomic
testing such as analyses of single nucleotide polymorphisms
that alter the activity of the cytochrome P450 enzymes [13]. 
CHALLENGES OF LEVERAGING PRECISION
MEDICINE FOR RARE DISEASES 
The “omics” technologies discussed above provide
tools for elucidating the etiology and pathogenesis of rare
diseases and identifying precision medicines for all patients
with these rare diseases. However, there are many chal-
lenges that can get in the way of effectively leveraging these
technologies for rare diseases, which can lack the large pa-
tient populations, coordinated army of scientific experts,
and funding to generate data on a scale large enough to
guide evidence-based practice. With 95 percent of rare dis-
eases not having a single Food and Drug Administration
(FDA)-approved therapy and few databases tracking treat-
ments used, important clinical data is never captured and
treating physicians are sometimes forced to make care de-
cisions based on anecdotal judgments [14,15]. Accessing
sufficient tissue samples for research is certainly one of the
greatest challenges for rare disease research. Unfortunately,
limited funding within the field can push researchers to
work more independently rather than cooperatively. In
some cases, researchers fight to keep their stored samples
from being shared with other institutions. Also, it can be
very difficult to generate sufficient data to win federal fund-
ing for diseases that are poorly understood, but scientific
understanding of these diseases cannot be furthered without
funding [14,16]. Finally, there are typically fewer experts
able to take on major translational research projects and
fewer pharmaceutical companies willing to fund rare dis-
ease studies. Of course, there are examples of rare diseases
with exemplar disease organizations, such as the Cystic Fi-
brosis Foundation, Progeria Research Foundation, PXE
(pseudoxanthoma elasticum) International, and Multiple
Myeloma Research Foundation, which have successfully
overcome these hurdles and proactively driven forward re-
search. One rare disease that is confronting the above chal-
lenges head on is Castleman disease (CD).
CHALLENGES FOR CASTLEMAN DISEASE 
RESEARCH
CD describes a heterogeneous group of disorders char-
acterized by abnormal proliferation of morphologically be-
nign lymphocytes due to excessive proinflammatory
hypercytokinemia, particularly Interleukin-6 (IL-6) [17].
The three disorders are unicentric CD (UCD), Human Her-
pes Virus-8 (HHV-8) associated multicentric CD (HHV-8-
associated MCD), and HHV-8-negative or idiopathic
multicentric CD (iMCD) (Table 1). Together, there are an
estimated 6,500 to 7,700 new cases diagnosed each year in
the United States [18]. 
Proliferation occurs in a single lymph node or region
of lymph nodes in UCD, and surgical resection of the af-
fected node(s) is usually curative [18]. Both HHV-8-asso-
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ciated MCD and iMCD are characterized by systemic
lymphadenopathy, polyclonal lymphocyte and plasma cell
proliferation, autoimmune manifestations, and multi-
organ system dysfunction [17]. Clinically, patients may
exhibit fevers, night sweats, weight loss, ascites, pleural
effusions, and organomegaly in the setting of systemic in-
flammation and laboratory abnormalities [19]. In HHV-8-
associated MCD, HHV-8 infects B-cells, evades host
immunity (most often in immunocompromized patients),
and replicates, producing lytic products that stimulate viral
IL-6 and signal human IL-6 release, which provokes an
inflammatory cascade [20]. Depletion of B-lymphocytes,
which host HHV-8, with rituximab is effective in a large
proportion of patients [21]. In HHV-8-negative iMCD pa-
tients, IL-6 and other proinflammatory cytokines also pro-
voke an intense inflammatory cascade. However, the
etiology, activated inflammatory pathways, diagnostic
biomarkers, and pathological cell types are unknown [17]. 
No formal diagnostic criteria exist for any form of
CD, and diagnosis is typically made by exclusion of other
disorders that can cause similar clinical and histopatho-
logic features [19]. Since the etiology and pathogenesis of
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Figure 1. Traditional research model.
In this model, 1) Disease Research Or-
ganizations (DRO) first provide support-
ive resources to and raise money from
patients and loved ones. 2) DROs also
often refer patients to a few expert
physicians, who collect clinical data and
tissue samples. 3) With funding in hand,
the DRO then places Request for Pro-
posals (RFPs) and invites researchers
to submit applications for funding. The
researchers located at institutions that
see the most patients clinically have ac-
cess to essential tissue samples and
clinical data, so they have the greatest
likelihood of winning competitive grants.
These individual researchers and the
DRO grant review committee, thus,
shape the research agenda for a given
disease. Occasionally, pharmaceutical
companies and governmental institu-
tions fund DROs to distribute grants for
research, but usually not until promising
preliminary data has been generated.
Table 1. Features of the different types of Castleman Disease.
Type of 
Castleman 
Disease
Unicentric
Multicentric
HHV8 positive
Multicentric
HHV8 negative
Type of 
Lymphadenopathy
Localized
Generalized
±hepatosplenomegaly
Generalized
±hepatosplenomegaly
Pathology
90% hyaline
vascular
plasmacytic or
plasmablastic
Mostly plasma-
cytic, but can
be hyaline vas-
cular or mixed
cellularity
IL6 driven 
inflammatory
syndromea
Typically not
Yes
Yes, but variable
clinical presenta-
tion from mild to
very severe and
some cases do
not respond to
anti-IL-6 therapy
Virologic Status
Negative for
HHV8 by QCPR
or Negative
LANA-1 stain
Positive for
HHV8 by QCPR;
May be positive
for HIV
Negative for
HHV8 by QCPR
or
Negative LANA-
1 stain,
Negative for HIV
Treatment
Complete 
Excision
Rituximab
±etoposide,
Optional 
valganciclovir
maintenance
Siltuximab,
Tocilizimab,
Rituximab,
In severe cases
Chemotherapy
aSymptoms: fevers, night sweats, anorexia, weight loss, fatigue. Laboratory abnormalities: anemia, thrombocytopenia or thrombocy-
tosis, elevated CRP, WESR, fibrinogen, hypergammaglobulinemia, abnormal renal function, increased IL6, VEGF, IL10.
iMCD have not been fully elucidated, a wide range of
treatments are used with variable effectiveness, including
cytotoxic chemotherapy, anti-IL-6 monoclonal antibodies,
rituximab, immunomodulators, and steroids. Anti-IL-6
therapy is the only therapy studied in a randomized con-
trolled trial, which demonstrated safety and efficacy for a
significant proportion of subjects [22]. Despite progress
for MCD, the largest and most recent case series found
that approximately 35 percent of MCD patients died
within 5 years [23]. 
CASTLEMAN DISEASE COLLABORATIVE 
NETWORK
The Castleman Disease Collaborative Network
(CDCN) was founded in 2012 to accelerate research and
drug development for CD by facilitating collaboration
among researchers and clinicians, investing funds in con-
sensus-prioritized projects, and supporting patients, their
families, and health care providers [24]. 
At the time of the CDCN’s creation, limited time and
money were being invested into elucidating the etiology
and pathogenesis of iMCD or UCD. The physicians and
researchers interested in CD were using different sub-clas-
sification systems to describe the disease, and there was no
consensus on diagnostic criteria. There was inaccurate in-
formation about epidemiology and prognosis from rep-
utable medical sources. The previously proposed model
of pathogenesis suggested that benign IL-6 secreting
lymph node tumors were the source of the CD inflamma-
tory storm even though all of the cells in the lymph node
were polyclonal [17]. 
Prioritizing Precision Medicine Research
The CDCN began by first creating a global commu-
nity of more than 300 researchers and physicians and as-
sembling a Scientific Advisory Board (SAB) comprised of
international CD experts. Based upon communication
among members of the CDCN network and a systematic
literature review, a new model of iMCD pathogenesis was
published in Blood that suggests that the enlarged lymph
nodes are reactive changes to the excess cytokines rather
than the root cause of the cytokines [17]. The paper also
proposed three hypotheses for what could be the mecha-
nism underlying the cytokine release. To test these hy-
potheses, the CDCN’s SAB developed a consensus
prioritized research agenda, termed the International Re-
search Agenda (IRA). Projects prioritized by the IRA in-
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Figure 2. CDCN’s research model. The CDCN has taken a four-step approach to drive forward “omics” research:
1a) The CDCN identified and connected the research community and (1b) provided supportive resources to patients
and loved ones. Then, the CDCN turns to the research community (2a) and patient community (2b) to prioritize key
research studies into an International Research Agenda as well as collect and centrally store clinical data and tissue
samples. With the top priority projects identified, the CDCN solicits funding from patients and loved ones for specific
projects. Then, the CDCN provides two mechanisms for funding: (3a) investigator-initiated research grants through
traditional requests for proposals and (3b) strategically directed research grants where the DRO recruits the top ex-
perts within the community or outside of the community to do the studies. 4) Pharmaceutical companies are more
eager to contribute tissue samples and funding for clearly defined projects with the greatest likelihood of return.
clude serum proteomics studies (data currently being ana-
lyzed), a pathogen discovery study to identify specific
viruses that may trigger iMCD using RNA sequencing (in
process), flow cytometry and immunohistochemistry to
identify pathological cell types involved in iMCD (in
process), whole exome sequencing of germline samples
(preparing to launch), and whole exome sequencing of CD
lymph nodes to search for somatic mutations (in the queue).
Since completing the IRA, the CDCN has been working to
execute it by recruiting academic collaborators and con-
tracting directly with contract research organizations
(CRO). Fundraising is provided first to the projects with the
highest near-term impact and the smallest relative financial
cost, chiefly through the engagement of patients and loved
ones to raise awareness within their own communities. 
Unlike the typical approach that many disease research
organizations take of first raising funds and then inviting
researchers to apply to use the funding how they see fit (Fig-
ure 1), the CDCN built a global community, leveraged the
community to prioritize research studies, recruited collab-
orators or CROs, and then raised funds to execute the com-
munity-prioritized research. The CDCN’s method enables
limited funding and tissue samples to be used most effi-
ciently, because the projects are determined based on the
consensus of the Scientific Advisory Board rather than in-
dividual priorities and capabilities [24] (Figure 2). 
Linking Natural History with the Genome
The CDCN is in the process of creating a hybrid global
patient registry and natural history study of CD, the AC-
CELERATE study. Accelerating Castleman Care with Elec-
tronic Longitudinal Registry, E-Repository, and Treatment
Effectiveness Research (ACCELERATE) will be an obser-
vational, web-based registry that combines clinical data
from patients internationally to aid in the understanding of
CD and facilitate further research projects. Slated to begin
enrollment in early 2016, ACCELERATE will generate data
on the diagnosis, treatment, and clinical outcomes of CD
[24]. The CDCN is also in the process of developing a
biobank to streamline the collection, storage, and process-
ing of blood and tissue samples from the CD community. 
Precision Medicine for MCD 
Currently, patients with MCD are treated distinctly
based upon the presence or absence of HHV-8 in lymph
node and blood samples. Patients infected with HHV-8 are
typically treated with rituximab based on its demonstrated
effectiveness and the basic understanding of B-lympho-
cytes hosting HHV-8 [20,21]. iMCD patients are treated
with a variety of different treatments, including therapy
targeting IL-6 with siltuximab or tocilizumab, rituximab,
immunosuppresants, corticosteroids, and cytotoxic
chemotherapy [25,26]. Siltuximab, an anti-IL-6 mono-
clonal antibody, became the first and only FDA- and
EMA-approved therapy for iMCD in 2014 [27]. The ap-
proval was based on positive data from the only random-
ized controlled trial that has ever been performed for
iMCD, which demonstrated significant symptomatic im-
provement and lymph node regression in 34 percent of pa-
tients on siltuximab versus 0 percent of patients on
placebo [28]. The CDCN’s most urgent priority is uncover
the molecular mechanisms of iMCD to determine what
other therapies may be effective in combination with or
as an alternative to siltuximab therapy in those that fail.
Discovery-level research approaches, including ge-
nomics, proteomics, and transcriptomics, will allow a pre-
cision medicine approach in iMCD by revealing biomarkers
that suggest clinically relevant subsets of patients, predict
impending disease activity, and/or predict which patients
will best respond to the specific therapies available. As
iMCD is a heterogeneous disease, diagnosis is nebulous,
and the best available treatment approach for an individual
patient is unknown. Identification of molecular subtypes of
iMCD should allow for more accurate diagnosis and treat-
ment, help with earlier intervention to prevent or reduce the
severity of active disease, and generate more personalized
information on disease course and outcomes.
Engaging the Community for Research
In addition to focusing on research priorities, en-
gagement of the global physician, researcher, and patient
community also has helped to facilitate research. The
CDCN provides up-to-date information to community
members and solicits feedback to build consensus among
members regarding the IRA. Importantly, the CDCN’s
culture of collaboration has enabled acquisition of clini-
cally annotated samples from around the world for
CDCN-funded research studies. Furthermore, the CDCN’s
online community enables rapid communication and hy-
pothesis generation. Also, CDCN leaders have completed
a systematic literature review, which synthesizes infor-
mation about clinical features of CD and specific re-
sponses to therapies [19], with the hope that this data can
be used to identify patient groups that may respond better
to one treatment than another (and corroborate these pa-
tient groups with “omics” data).
CONCLUSION AND OUTLOOK
It is not possible to advance understanding, research,
and treatment for rare diseases like CD without highly struc-
tured, goal-directed, global collaboration. The inclusive,
multi-faceted network provided by the CDCN is of tremen-
dous value as it facilitates scientific discovery and supports
scientists, who can often struggle to identify funding and tis-
sue samples to test their hypotheses. 
Precision medicine research facilitates discovery of
novel treatments and has the potential to identify the spe-
cific patients who will benefit from these treatments [3].
Organizations that facilitate genomics and proteomics re-
search have the potential to generate crucial data that will
transform diagnosis and care of CD. In this respect, the
CDCN’s infrastructure may serve as a model for other rare
disease organizations to facilitate efficient, high-impact
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translational research that will improve outcomes for thou-
sands of patients. 
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